{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:26:16Z","timestamp":1787840776997,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    The study was conducted to determine the global prescribing behavior for amyloidosis secondary to rheumatoid arthritis (RA) and to determine the drug-specific treatment response. We checked comprehensive databases like Embase, Scopus, PubMed, and Web of Science to assess the research papers thoroughly. Studies happened from January 2001 to June 2025, were considered. Observational cohort studies reporting RA amyloidosis treatment were considered to assess naturalistic prescription patterns. Research paper quality was checked for risk of bias using a validated tool. Meta-analysis was performed with R. The study\u2019s primary outcome was to assess prescription pattern in a naturalistic, non-controlled manner. Secondary outcome was to assess the effect of different treatment agents on c-reactive protein (CRP), serum creatinine, and proteinuria in a pre-and post-treatment fashion. Twelve observational studies were identified with confirmed diagnoses in 463 RA amyloidosis patients. Etanercept was observed as the most prescribed drug. P-score for Infliximab was highest for creatinine-reducing capacity. The odds of reducing proteinuria were maximum with rituximab (OR = \u22124.35; C.I. = \u221210.24-\u22121.54). Safety endpoint assessment showed a lower risk of infection with Etanercept (OR = 0.14; C.I. = \u22120.06-0.30) and highest mortality with cyclophosphamide (OR = 0.42; C.I. = \u22120.30-0.55). Heterogeneity was high in present meta-analysis (I\n                    <jats:sup>2<\/jats:sup>\n                    = 72%). Etanercept was most preferred treatment option for RA amyloidosis on both descriptive and inferential statistical assessment. Network meta-analysis can be utilized for prescription pattern assessments.\n                  <\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1084_25","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:00:25Z","timestamp":1774008025000},"page":"511-519","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prescription pattern assessment of pharmacotherapeutics used in the management of amyloidosis secondary to rheumatoid arthritis via systematic review and network meta-analysis"],"prefix":"10.4103","volume":"15","author":[{"given":"Aayush","family":"Sehgal","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, G.H.G Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A.","family":"Shamim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, G.H.G Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol N.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen C.","family":"Hegde","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[{"name":"Amity School of Pharmaceutical Sciences, Amity University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joban Preet Singh","family":"Deol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Naidu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"R1-20260325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis:A brief overview of the treatment","volume":"27","author":"Bullock","year":"2019","journal-title":"Med Princ Pract"},{"key":"R2-20260325","doi-asserted-by":"crossref","first-page":"848427","DOI":"10.3389\/fpsyt.2022.848427","article-title":"The effects of patient education on psychological status and clinical outcomes in rheumatoid arthritis:A systematic review and meta-analysis","volume":"13","author":"Wu","year":"2022","journal-title":"Front Psychiatry"},{"key":"R3-20260325","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis:an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"R7-20260325","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics:Target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R8-20260325","first-page":"850","article-title":"Amyloid A amyloidosis secondary to rheumatoid arthritis:Pathophysiology and treatments","volume":"29","author":"Nakamura","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"R9-20260325","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R10-20260325","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol Med"},{"key":"R11-20260325","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis:Epidemiology, diagnosis, and management","volume":"6","author":"Real","year":"2014","journal-title":"Clin Epidemiol"},{"key":"R13-20260325","doi-asserted-by":"crossref","first-page":"755844","DOI":"10.3389\/fimmu.2021.755844","article-title":"Toward overcoming treatment failure in rheumatoid arthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R15-20260325","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41598-022-06584-y","article-title":"Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions","volume":"12","author":"Larid","year":"2022","journal-title":"Sci Rep"},{"key":"R16-20260325","doi-asserted-by":"crossref","first-page":"1037983","DOI":"10.3389\/fphar.2022.1037983","article-title":"An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"13","author":"Vugler","year":"2022","journal-title":"Front Pharmacol"},{"key":"R17-20260325","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31138\/mjr.30.3.141","article-title":"Twenty years of targeted treatment in rheumatoid arthritis in the Greek databases:Achievements and unmet needs","volume":"30","author":"Sidiropoulos","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"R18-20260325","first-page":"255","article-title":"Prescribing trends in disease-modifying antirheumatic drugs for rheumatoid arthritis:A survey of practicing Canadian rheumatologists","volume":"29","author":"Pope","year":"2002","journal-title":"J Rheumatol"},{"key":"R19-20260325","doi-asserted-by":"crossref","first-page":"631299","DOI":"10.3389\/fimmu.2020.631299","article-title":"Serum amyloid A in inflammatory rheumatic diseases:A compendious review of a renowned biomarker","volume":"11","author":"Sori\u0107Hosman","year":"2021","journal-title":"Front Immunol"},{"key":"R20-20260325","doi-asserted-by":"crossref","first-page":"1144397","DOI":"10.3389\/fimmu.2023.1144397","article-title":"Case report:Rapid development of amyloid A amyloidosis in temporal arteritis with SAA1.3 allele;An unusual case of intestinal amyloidosis secondary to temporal arteritis","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Immunol"},{"key":"R21-20260325","doi-asserted-by":"crossref","first-page":"w14030","DOI":"10.4414\/smw.2014.14030","article-title":"Cyclophosphamide:As bad as its reputation?Long-term single-centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"R24-20260325","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/jcm10245847","article-title":"Rituximab therapy for adults with nephrotic syndromes:Standard schedules or B cell-targeted therapy?","volume":"10","author":"Del","year":"2021","journal-title":"J Clin Med"},{"key":"R25-20260325","first-page":"1578","article-title":"A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","volume":"65","author":"Klareskog","year":"2006","journal-title":"Etanercept Study 301 Investigators"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1084_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:28:43Z","timestamp":1787837323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1084_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1084_25","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-06-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}